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Summary 
Numerous studies of a much varied nature have been 
conducted on the roots of Asian (Chinese or Korean) ginseng 
(Panax ginseng C.A. Meyer, Araliaceae). Steamed and dried 
(red) Asian ginseng has been recognized as being apprecia-
bly more biologically active than the raw unprocessed (often 
scraped or peeled) and dried (white) ginseng root in some 
notable respects. For example: free-radical scavenging, antiox-
idant, “anxiolytic-like,” and anti-tumor promoting activities. 
Much less investigation has been directed towards American 
ginseng (P. quinquefolius L.). However, in recent years Cana-
dian researchers have demonstrated its activity in treating 
Type 2 diabetes and developed a special patented polysaccha-
ride fraction that has shown effectiveness in the prevention 
and treatment of upper respiratory tract infection. 
Ginsenosides, the dammarane-type triterpene saponin 
constituents of Panax species, are generally considered the 
main active components of the plant roots used for medicinal 
purposes. The normally analyzed neutral ginsenosides vary in 
level and ratio among the different Panax species, and they 
are accompanied in unprocessed root by acid derivatives of 
malonic acid. These derivatives are readily hydrolyzed by the 
steaming process, which converts “white” ginseng to “red” 
ginseng (actually caramel-colored). The steaming process 
also converts original ginsenosides to partially deglycosyl-
ated derivatives that have enhanced anti-cancer activity (e.g., 
ginsenosides Rg3, Rg5, and Rh2). The other main pharma-
cological activities claimed for ginseng extracts, as well as for 
individual ginsenosides, have been 
antioxidant (Rb1), calcium chan-
nel inhibition (Rf), immunomodu-
lation (Rg1), neuroprotection (Rb1), 
and platelet inhibition. Diacety-
lene constituents (usually referred 
to incorrectly as “polyacetylenes”) 
have also been implicated in plate-
let inhibition and in tumor inhibi-
tion activities, while polysaccharides 
have been claimed to be involved 
in cytoprotection, immunomodula-
tion, and tumor inhibition actions. 
Introduction
Of the 3 prominent commer-
cial ginsengs, Asian ginseng (Panax 
ginseng) is perhaps the most revered 
of traditional Chinese medicines. 
It is native to China, Russia, and 
Korea, and most of the commercially 
exported supply comes from China 
and Korea. While the use of Asian 
ginseng is widely believed to span 
at least 2000 years, Chinese use of 
American ginseng (P. quinquefolius) 
began only about 300 years ago. 
American ginseng is native to eastern North America and is 
mostly cultivated today in the provinces of British Columbia 
and Ontario in Canada and in the state of Wisconsin in the 
United States. Commercial cultivation of American ginseng 
in China was started in 1980. Sanchi or tienchi ginseng (P. 
notoginseng [Burkill] F.H. Chen ex C.Y. Wu & K.M. Feng) 
is popular in Asia where it is used as a hemostatic agent for 
blood-regulating purposes and also as a cardiotonic treat-
ment. 
American vs. Asian Ginseng: Ginsenoside Levels and 
Profiles
Neutral Ginsenosides
The root of these 2 most commercially prominent Panax 
species have been found to contain more than 30 triterpene 
dammarane-type saponins (mostly neutral ginsenosides) to 
which are attributed most of ginseng’s pharmacological activi-
ties. Quantitative analysis for ginsenosides characterized as 
Rx—according to their mobility on thin-layer chromato-
graphic (TLC) plates, with polarity decreasing from index “a” 
to “h”—has focused on the neutral ginsenosides Rb1, Rb2, 
Rc, Rd (derivatives of protopanaxadiol), and Re, Rf, Rg1, and 
Rg2 (derivatives of protopanaxatriol) (see Figure 1). Earlier 
methods of analysis, such as colorimetry and gas chromatog-
raphy, are non-specific and led to exaggerated and incorrect 
results, as compared to high-performance liquid chromatog-
This paper is dedicated to the memory of Professor Ying-jie Chen (1936-2003) of Shenyang Pharmaceutical University, PRC, 
who died during preparation of a book extensively covering the chemistry and pharmacology of ginsenosides. 
Figure 1. Prominent protopanaxadiol and protopanaxatriol glycosides from P. ginseng and 
P. quinquefolius
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raphy (HPLC) values. HPLC has been employed since 19801 
and was later refined using a programmed elution technique 
with photodiode array detection to allow separation of all 8 
major ginsenosides in one analytical run.2
In view of the historical variation in analytical tech-
niques employed, the published analytical data for ginsen-
oside content of ginseng roots are inconsistent and cannot 
be pooled. In addition, earlier data apply not only to reliably 
identified raw material but also to commercial material of 
questionable species and plant part identities. This situation 
makes it difficult to accurately establish the superiority of 
ginsenoside content within P. quinquefolius root over the root 
of P. ginseng, as is widely appreciated.3  
However, analysis of dried 4-year-old roots of American 
ginseng taken from cultivated commercial fields in 9 differ-
ent locations in British Columbia, Canada, in 1994 revealed 
an average of 3.00% (2.44-3.88) total for the 6 major 
ginsenosides (i.e., Rb1, Rb2, Rc, Rd, Re, and Rg1).4 Rf is 
absent from P. quinquefolius and Rg2 is present at such low 
levels in both P. quinquefolius and P. ginseng that ginsenosides 
Rb1 and Re together accounted for better than 75% of the 
total ginsenoside complement. Another study reported an 
average of 4.04% from a total of the 8 main ginsenosides 
in 3 cultivated American ginseng roots.5 However, Court et 
al indicate approximately 8% total ginsenosides in 4-year-
old American ginseng roots when taking into consideration 
the content of malonyl ginsenosides (see later under Acidic 
Ginsenosides). The ratio of Rb1 to Rg1, often used as one 
basis for distinguishing between the two Panax species, 
ranged from 2.91 to 13.28, with an average of 7.54. In yet 
another study, 23 purported American ginseng root samples 
exhibited a ratio of 7.69, while the ratio found for 20 Asian 
ginseng samples was 1.30; the ratio for P. ginseng usually falls 
between 3 and 1.1 
The data from analysis of P. ginseng roots are more sparse, 
with only two publications standing out, one dealing with 
commercial products and the other with cultivated 5-year-old 
Asian Ginseng Panax ginseng. Photo ©2008 Steven Foster
Figure 2. Structures of ginsenoside Rf and 24(R)-
pseudoginsenoside F11
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roots from China.5 The latter publication reported an aver-
age of 1.49% from a total of the 8 main ginsenosides plus the 
oleanolic ginsenoside Ro in 7 samples (1.27% without Ro), 
while the former publication reported an average of 1.47% 
of the 8 main ginsenosides from 8 purported P. ginseng root 
samples in hard gelatine capsules (1 sample was totally devoid 
of ginsenosides). It should be noted that one has no assur-
ance of what part of the root/rhizome is employed in prepara-
tion of commercial root products. Further, the average values 
found from 20 4-year-old P. ginseng plants from Korea were 
1.348, 3.532, and 6.148% from the main root, lateral roots, 
and “root hairs” (rootlets).1 However, neither an average for 
the total root content nor ratios of the respective root parts 
were determined. In 1995, HPLC was used to evaluate the 
ginsenoside content of more than 60 commercial products, 
purportedly from various Panax species, as well as from a vari-
ety of roots and tissue culture samples derived from P. ginseng 
root.6 Widely differing levels and proportions of ginsenosides 
were observed. The results from this analysis of commercial 
products emphasize the need for careful attention to quality 
control.6 
Distinguishing American and Asian Ginsengs
The pure root of American ginseng can be really distin-
guished from the pure root of Asian ginseng by HPLC analy-
sis. American ginseng is devoid of ginsenosides Rf and Rg2, 
while Asian ginseng contains relatively low concentrations 
of Rf and Rg2. A not uncommon problem involves either 
substitution or adulteration of the more expensive American 
ginseng with sun-dried Asian ginseng.7 Scientists at Shenyang 
Pharmaceutical University in the People’s Republic of China 
developed a TLC method by which, at 4º C, ginsenoside Rf 
was revealed in Asian ginseng and the ocotillol-Type 24(R)-
pseudoginsenoside F11 was revealed in American ginseng8 (see 
Figure 2). Scientists at the University of Illinois in Chicago 
subsequently developed an HPLC procedure with evaporative 
light scattering detection for determination of 24(R)-pseu-
doginsenoside F11.9 Gas chromatographic-mass spectromet-
ric (GC/MS) analysis has revealed that American ginseng 
contains more than 0.1% of 24(R)-pseudoginsenoside F11, 
which is over 1000 times the content found in Asian ginseng 
(less than 0.0001%).10
Application of the TLC procedure to 43 samples of purported 
“Radix quinquefolium and its preparations” purchased in 
China showed that 18 samples (44.3%) were either P. ginseng 
or mixtures of P. ginseng and P. quinquefolius.8 
Acidic Ginsenosides
Of the more than 30 ginsenosides so far identified in 
Panax spp., 5 are acidic, bearing carboxylic acid functions. 
Four of these are mono-esters of the dicarboxylic acid, malo-
nic acid (one carboxylic acid function condensing with the 
primary alcoholic group at C-6 of the terminal glucosyl ring 
attached to C-3 of the triterpene skeleton); malonyl (m) Rb1, 
mRb2, mRc and mRd occur in both American and Asian 
ginseng, as does the 5th acidic ginsenoside, Ro, an oleanolic 
acid derivative. Originally identified as chikusetsu saponin 
V in the rhizome of Japanese ginseng (P. japonicus [T. Nees] 
C.A. Meyer), Ro bears a carboxylic acid function at C-6 of 
the proximal glucose function at C-3 of the triterpene ring 
system11 (see Figure 3). 
The malonyl ginsenosides (see Figure 4) are more polar 
and water soluble than the neutral ginsenosides to which 
they are readily converted by hydrolysis, accelerated by heat, 
and catalyzed by both acid and base. As such, no malonyl 
ginsenosides have been detected in steam-processed ginseng 
root (red ginseng) or cooked Chinese shihchu ginseng.3 HPLC 
protocols normally employed in the estimation of ginsenoside 
content do not measure the acidic malonyl ginsenosides and 
therefore underestimate total ginsenoside values.12
HPLC procedures using reversed-phase C18 columns and 
gradient elution systems, such as those published by Samu-
kawa et al,13 allow separation and estimation of 22 major and 
minor, both neural and acidic ginsenosides. Kitagawa et al14 
compared white and red ginseng prepared from the same P. 
ginseng roots and noted appreciable concentrations of the 4 
malonyl ginsenosides in white, but not in red ginseng. Chuang 
et al3 analyzed 10 samples of white Asian ginseng collected 
from herb shops throughout Taiwan and characterized the 
samples by comparing features of external appearance and 
histological anatomy. The levels of the 4 malonyl ginsenosides 
and their ratios to their neutral progenitors were considerably 
Figure 4. Malonyl ginsenosidesFigure 3. Ginsenoside Ro
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lower than those found in the 2 samples of American ginseng 
examined. For example, an average of 3.0 was found for the 
ratio of Rb1 to mRb1 in the Asian samples, while values of 
0.90 and 0.80 were found for the two 4-year-old American 
roots grown in Ontario, Canada. Between completion of the 
1st and 4th years of growth, the total content of 6 of the main 
ginsenosides (minus Rf and Rg2) increased from approxi-
mately 3% to almost 8%, of which over 50% was due to 
combined Rb1 and mRb1 ginsenosides.15
Court et al16 estimated the malonyl ginsenosides indirectly 
by first determining the neutral ginsenosides, hydrolysing 
the acidic ginsenosides with 5% potassium hydroxide, and 
then re-analyzing for neutral ginsenosides. A more recent 
study determined that extraction of ginseng roots with liquid 
ammonia was about twice as efficient as extraction with 
methanol/water (60:40; v/v) and effected efficient conver-
sion of mRb1, mRb2, mRc, and mRd to their corresponding 
neutral ginsenosides.17 
It is worth noting that considerable variability of ginsenoside 
content occurs in ginseng raw roots, as well as root products. 
As Court has observed, considering the established differ-
ences in content of main root, lateral roots, and rootlets, it is 
essentially important to carefully mix powdered whole root 
“prior to filling non-assayed capsules with measured amounts 
of powdered root.”1,18,19 Even with carefully standardized 
extraction methods and estimation of total ginsenosides, 
Soldati and Sticher found up to 3-fold variation in individual 
ginsenoside levels within 3 lots of extract standardized to 
roughly 4% total ginsenosides and within 4 lots of extract 
standardized to 7.2-7.5% total ginsenosides (extracts were in 
soft gelatin capsules).1 Such variation could conceivably have 
an impact on pharmacological activity.   
Other Pharmacologically Active Ginseng Constituents
While it is widely believed that ginsenosides are the main 
active constituents of ginseng roots, responsible for a wide 
range of biological activities,7 other constituents, nota-
bly polysaccharides, polypeptides, diacetylenes (erroneously 
referred to as “polyacetylenes”), and alkaloids, have also been 
implicated in a variety of activities.
The isolated diacetylenes—mainly panaxytriol, panaxynol, 
and panaxydol (see Figure 5)—show cytotoxic, antiplatelet, 
and anti-inflammatory effects, respectively.2 The ginsenans 
PA, PB, S-IA, S-IIA and some other polysaccharides exhibit 
immunological activity such as reticuloendothelial system 
potentiation, effects on the body’s unspecific immune system, 
and alkaline phosphatase-inducing activity.2 Lee et al found 
that ginsan, a purified lectin-free acidic polysaccharide from 
P. ginseng (molecular weight about 150,000), stimulated 
the proliferation of B-cells and T-cells and the cytotoxicity 
of spleen cells to a wide range of tumor cells in vitro. The 
ginsan also activated macrophages to generate nitrogenous 
intermediates and become in vivo active against B16 mela-
noma cell lines found in the benzo[a]pyrene-induced autoch-
thonous lung tumor model.20 Recently, pre-treatment with 
ginsan (25µg/kg) was shown to protect mice from lethality 
induced by Staphylococcus aureus challenge.21 Panaxans have 
been identified in 2 series from P. ginseng, namely, A-E from 
Chinese or Korean roots22 and Q-V from Japanese roots.23 
(Note: Panaxans are peptidoglycans, i.e., polymers composed 
of polysaccharide and peptide [condensed amino acid] 
chains.) All these panaxans showed dose-dependent hypo-
glycemic activity in normal and alloxan-induced diabetic 
mice when administered by intraperitoneal injection, but 
were ineffective when given orally. Presumably this occurred 
because the high polymer glycans are unlikely to be absorbed 
from the gastrointestinal tract, probably due to degradation 
by peptidase and glycosidase enzymes secreted by the gut 
and by colonic microflora in the large bowel. Quinquefolans 
A-C from American ginseng have also shown marked blood-
glucose-lowering effects when administered to both normal 
and alloxan-induced hyperglycemic mice.24 Wang et al have 
also noted a hypoglycemic effect of ginseng polypeptides.25, 
26  
Anti-carcinogenic Activity
Shibata et al demonstrated that partially deglycosylated 
ginsenosides produced during the steaming process, but 
also by metabolic transformation through the agency of 
human intestinal bacteria, have enhanced biological activity, 
particularly anti-carcinogenic. This is likely the 
result of increased bioavailability of the degraded 
original ginsenosides.27 Prominent among such 
ginsenosides detected in Korean red ginseng are 
Rh1, Rh2, Rg3, and Rg5; Rh1 is derived from 
protopanaxatriol (PPT) ginsenosides, such as Rg1, 
while Rh2, Rg3, and Rg5 are derived from 
protopanaxadiol (PPD) ginsenosides (see Figure 
6). Other degraded raw ginseng ginsenosides, 
produced by hydrolysis, isomerization at C-20, 
and dehydration, are present in relatively minute 
quantities. Shibata cites other researchers as estab-
lishing that Rg3 inhibits in vitro cancer cell 
invasion and metastasis; Rh2 inhibited human 
cancer cell growth in nude mice. Yun identified 
Rh1, Rh2, Rg3, and Rg5 as the major saponin 
components in Korean red ginseng; Rg3 and Rg5 
showed statistically significant reduction of lung 
tumor incidence, while Rh2 had a tendency to 
prevent non-organ-specific cancer in humans.28 
Figure 5. Ginseng diacetylenes
Park et al demonstrated the cytotoxicity of dammarane-
type glycosides from steam-processed P. ginseng—namely 
Rg3, Rg5, Rk1, Rs4, and Rs5, having 50% growth inhi-
bition concentrations of 41, 11, 13, 37, and 13 microM, 
respectively29—against SK-HeP-1 hepatoma cancer cells.30 
A recent double-blind placebo-controlled trial of so-called 
“Sun Ginseng” (high-pressure steam-processed P. ginseng) 
claimed the treatment to be beneficial in improving qual-
ity of life in cancer patients, mainly those suffering from 
gynecologic or hepatobiliary cancer.31 However, the authors 
of the study report neither the details of preparation of 
the tested item nor the vehicle of administration. Regard-
ing chemical composition, the publication states that Sun 
Ginseng contains different types of ginsenosides, such as 
Rs4, Rs5, Rs6, and Rs7 (structures not presented), which 
were not mentioned in the previously cited publication. 
The latter study claimed that the levels of ginsenosides 
F4, Rg3, and Rg5 (absent from raw ginseng) are progres-
sively elevated with increasing steam temperature. Rg3 and 
Rg5 attained values of 39% and 19%, respectively, of total 
ginsenosides at 120o C under autoclaving for 2 hours.32 Of 
the 3 products, when steamed at 100, 110, and 120o C, the 
last was most potent in the ability to induce endothelium-
dependent relaxation. 
Steam-processed North American ginseng has not been 
subjected to chemical or biological evaluation, but an in 
vitro study with MCF-7 breast cancer cells showed that a 
standardized extract of unprocessed P. quinquefolius root 
synergistically inhibited cell growth when combined with 
standard chemotherapeutic agents.33
Anti-diabetic Clinical Trials
In 1995, the late E.A. Sotaniemi and coworkers reported 
that treatment with an unspecified ginseng extract—
presumably from P. ginseng root—improved fasting glyce-
mia and long-term glycemic control, as assessed by glycosyl-
ated hemoglobin (HbA1c) in 36 Type 2 diabetic subjects.34 
However, the results of that study were ambiguous because 
of significant weight loss differences between treatment 
groups, as well as poorly described statistics. In 2000, Tetsu-
tani and coworkers reported that treatment with a Korean 
red ginseng extract decreased HbA1c in 34 patients with 
Type 2 diabetes, as compared to controls.35 However, subject 
selection, allocation to treatment, statistics, and follow-up 
of the study were poorly described. In the years 2000 and 
2001, Vuksan, Sievenpiper, and coworkers published the 
results of 5 randomized, placebo-controlled clinical trials 
with American ginseng whole root for glycemic control, 
summarized and discussed in a 2005 publication.36 Ameri-
can ginseng reduced post-prandial glycemia from 9.1% to 
38.5%, doses of 1 to 9 g being equally efficacious from 0 
to 120 minutes before the glucose challenge in diabetic 
subjects—without interaction with background antihyper-
glycemic medication—but glycemia only being reduced in 
nondiabetic subjects if the treatment was administered at 
least 40 minutes before the glucose challenge. A subsequent 
trial with a different batch of American ginseng from the 
same supplier was unsuccessful to reproduce the post-pran-
dial effects observed with the original batch, an outcome 
attributed to “a depressed ginsenoside profile.”37 Further-
American Ginseng Panax quinquefolius. Photo ©2008 Steven Foster
Figure 6. Main ginsenoside products of steamed P. ginseng root
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more, the authors of the study opine that “Although 
ginsenoside differences are probably driving effects, 
other components such as quinquefolans (peptidogly-
cans) and ginsenans (glycans) might share some respon-
sibility.” A third batch of American ginseng exhibited 
acute post-prandial glycemic-lowering efficacy similar 
to the first, as did Vietnamese ginseng (P. vietnamensis 
Ha & Grushv.), whereas Japanese ginseng (P. japoni-
cus), Asian red (steamed root), and Sanchi ginseng (P. 
notoginseng) had null effects; Asian and American wild 
ginsengs raised glycemia.38 
Vuksan et al demonstrated that 12 weeks of supple-
mentation with 6 g/day of a selected Korean red ginseng 
(P. ginseng) rootlets product, as an adjunct to conven-
tional antidiabetes therapy, maintained good glycemic 
control and improved plasma glucose and insulin regu-
lation safely beyond usual therapy in patients with well-
controlled Type 2 diabetes.39 However, clinical efficacy 
as assessed by HbA1c was not demonstrated, and future 
studies using intention-to-treat analysis are needed 
to determined whether this treatment is efficacious 
as a monotherapy in people with less well controlled 
diabetes. The total ginsenoside contents reported for 
6 and 8 of the main ginsenosides in the efficacious 
American ginseng root and Korean red ginseng rootlet 
products were 3.21 and 1.92%, respectively, while that 
of the ineffective American ginseng root was 1.66%. 
However, efficacy of these products and the varied 
glycemic activities of the 5 different Panax species38 
might be easily reconciled with either the levels of 
individual ginsenosides or the various ratios calcu-
lated, such as protopanaxadiol (PPD): protopanaxa-
triol (PPT) ginsenosides, Rb1: Rg1, Rb1: Rc and Rg1:
Re. For example, the ratio Rb1:Rg1, the most prevalent 
PPD and PPT ginsenosides, respectively, for American 
ginseng was 15.3 and only 0.94 for Korean red. Also, 
while ginsenoside Rb2 has been found to be the most 
effective ginsenoside for decreasing blood glucose levels 
in streptozotocin-induced diabetic rats by intraperito-
neal injection,40 its level in ginseng root was relatively 
low, being 0.06 and 0.25% in American and Korean 
red rootlet, respectively. Additionally, while ginsenoside 
Re has been identified as a prominent active principle 
in P. ginseng berry extract—at a level similar to that in 
efficacious P. quinquefolius—and found to exert signif-
icant anti-hyperglycemic effect intro-peritoneally in 
obese diabetic mice,41 its level in the efficacious Korean 
red ginseng rootlet material was only 0.03% and was 
not a significant predictor of glycemic lowering efficacy 
in multiple regression models applied by Sievenpiper 
and associates. Finally, while ginsenoside Rg1 has been 
shown to decrease blood glucose in resting mice by 16% 
when administered by stomach intubation, its level was 
highly variable in the various ginsengs tested, being 
0.13 and 0.43 in efficacious American and Vietnamese 
ginsengs, but 1.74 in ineffective Sanchi ginseng.38
Of the other non-ginsenoside constituents considered 
as potential contributors to ginseng’s antihyperglycemic 
activity, the peptidoglycan panaxan B has been shown 
to have significant effect in mice.42 However, as indi-
Asian Ginseng Panax ginseng. Photo ©2008 Steven Foster
Figure 7. Pathways of intestinal bacterial hydrolysis for protopanaxadiol 
ginsenosides
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cated earlier, a reservation remains regarding the poten-
tial activity of peptidopolysaccharides by oral administra-
tion because peptidase and glycosidase enzymes secreted 
by gut and colonic microflora in the large bowel would 
likely degrade peptidoglycans to their base sugar and 
amino acid units. It should also be noted that analysis for 
glycans and peptidoglycans has not been applied to the 
various ginseng root samples tested for antihyperglycemic 
activity. However, it is interesting to note that Han et al 
used an alcan blue dye complex formation to confirm that 
the polysaccharide yield from Korean red ginseng was 3 
times greater than from fresh root, which is likely due to 
hydrolysis of lignin-bound polysaccharides.43 Further-
more, main roots yielded more polysaccharide than root-
lets, polysaccharides being located mainly in the cortex 
and cambium. 
Variability and Standardization
Vuksan and coworkers have stated that “In the absence 
of adequate standardization to support therapeutic indica-
tions, one cannot be assured of reproducible results with 
other [than tested] sources.”37 Vuksan also warns against 
“standardization that is without basis”38 and emphasizes 
the “need to develop a basis for standardization that ties 
the composition of herbs to efficacy.”36
Ginsenoside Metabolism
Towards the end of the last century, research on 
ginsenosides focused on their metabolism by intestinal 
bacterial flora. Notably, Korean and Japanese researchers 
demonstrated that ginsenosides containing two (bisdes-
mosides) or more glycoside moieties (e.g., the PPT ginsen-
oside Re) are not appreciably absorbed from the gastro-
intestinal tract.12,44 Both PPD and PPT ginsenosides, 
such as the dominant Rb1 and Rg1, are largely elimi-
nated unchanged. Only deglycosylated derivatives attain 
appreciable levels in plasma, following intestinal bacte-
rial metabolism (IBM): Rb1 to compound K (IBM I) via 
Rd (see Figure 7) and Re to Rh1 via Rg1 (see Figure 8). 
So, while Re from P. ginseng berry is an effective anti-
diabetic agent when injected in mice,42 it is highly likely 
that its effectiveness would be considerably reduced by 
oral administration. If an effective oral human dose of 
Asian ginseng berry extract could be achieved, the true 
active principle would likely be ginsenoside Rh1, which 
incidentally is produced from steamed (red) ginseng root. 
The earlier observed antihyperglycemic ineffectiveness of 
white Asian and Asian red ginseng root38 may have been 
largely due to reduced ginsenoside content (as compared 
to Asian ginseng rootlets).  
A thorough examination of the composition and anti-
hyperglycemic activity of American red ginseng is sorely 
needed.
Immunomodulatory Effects  
In vitro
A variety of immunological effects have been demon-
strated in vitro for ginseng root extracts, fractions, and 
American Ginseng Panax quinquefolius. Photo ©2008 Steven Foster
Figure 8. Intestinal bacterial metabolism of ginsenoside Rg1
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isolated principles.45 Alcohol-insoluble fractions are composed 
almost exclusively of polysaccharides and oligosaccharides 
and are much more potent than alcohol-soluble fractions 
composed of ginsenosides.46 Most of the in vitro studies have 
been conducted with polysaccharide-rich extracts or isolated 
polysaccharides from P. ginseng root.46,47 Only 2 studies have 
been conducted from isolated polysaccharides48 and active poly-
saccharide fractions from P. notoginseng.49 One study has been 
conducted from a proprietary aqueous extract (CVT-E002) of 
P. quinquefolius.46 
The ethanol-insoluble fraction of an aqueous extract of P. 
ginseng was found to induce proliferation of splenocytes and to 
generate activated killer cells.50 The activated killer cells neutral-
ized both NK cell-sensitive and insensitive tumor target cells 
without MHC-restriction. Two extracts of P. ginseng have also 
been found to activate components of cell-mediated immunity, 
increasing the phagocytosis index along with phagocytosis frac-
tion.51 
Two acid polysaccharides isolated from P. ginseng root extract, 
named ginsenan PA and ginsenan PB, exhibited similar reticu-
loendothelial system (RES), anti-complementary, and alkaline-
phosphatase-inducing activity.52 Pectic polysaccharides from the 
root of P. ginseng have been found to exert potent gastric cyto-
protective and anti-ulcer effects.53  
Immunostimulating activity of Panax has also been observed 
in polysaccharide-containing material extracted from the leaves 
of P. ginseng.52 Rhamnogalactouronan II isolated from the leaves 
enhanced macrophage Fc receptor expression.54 An anti-ulcer 
pectic polysaccharide has also been characterized from leaves of 
P. ginseng.55  
In one study, immunomodulating polysaccharides were 
isolated from P. notoginseng. In another study, a RES-active 
polysaccharide, sachinan A,48 and 4 distinct homogeneous 
active polysaccharide fractions49 were isolated from the roots of 
P. notoginseng. In the latter study, one fraction showed strong 
anti-complementary activity, two fractions significantly induced 
the production of interferon-γ in the presence of concanavalin-
A, and all fractions induced the production of TNF-α, using 
human serum and antibody-sensitized sheep red blood cells. 
One in vitro study with a P. quinquefolius extract (the afore-
mentioned proprietary product CVT-E002) found stimulation 
of the proliferation of normal mouse spleen cells, of which the 
Left Photo: Author Dr. Dennis Awang inspecting American Ginseng (Panax quinquefolius).
Right photo: Author Dr. Michael Li holding an American Ginseng (Panax quinquefolius).
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major responding subpopulation was identified as B lymphocytes. 
CVT-E002 also activated peritoneal exudates macrophages, 
which lead to enhanced interleukin-1 (IL-1), interleukin-6 (IL-6), 
tumor necrosis factor-α (TNF-α), and nitric oxide (NO) produc-
tion. In addition, CVT-E002 stimulated in vivo immunoglobulin 
G (IgG) production in treated mice.46 A subsequent ex vivo study 
using C57 BL/6 mice demonstrated that CVT-E002 could signif-
icantly increase Con-A-induced IL-2 and IFN-γ productions in 
spleen cells in a dose-dependent manner.56
Ginsenoside Rg1 has been tested for stimulatory effect on 
immune function of lymphocytes in the elderly.57 Rg1 was found 
to stimulate proliferation of lymphocytes and to increase the 
fluidity of lymphocyte membrane in the aged.
Clinical Studies 
During the cold and flu seasons of 2000 and 2001, CV Tech-
nologies, Inc. (Edmonton, Alberta, Canada) conducted 2 Phase 
II randomized, double-blind, placebo-controlled clinical trials 
(RCT) with their proprietary American ginseng root aqueous 
extract, CVT-E002.56,58 The trials compared CVT-E002 with 
placebo in preventing acute respiratory illness (ARI) in institu-
tionalized older adults (> 60 yrs). The preparation was described 
as containing 80% poly-furanosyl-pyranosyl-saccharides and 10% 
protein in a 2004 publication of the results of the combined Phase 
II trials.59 The primary endpoint was clinically confirmed ARI, 
which is defined as the onset of respiratory symptoms (cough, 
sore throat, nasal or sinus congestion, runny nose) plus one addi-
tional respiratory or constitutional symptom (fever, headache, 
fatigue, myalgia, etc.). The secondary endpoints included severity 
and duration of respiratory illness, laboratory confirmed respira-
tory illness or influenza, and severity and duration of influenza. 
Although the odds for developing ARI defined by symptoms 
alone were not significantly reduced in the treatment group, the 
odds ratio for laboratory-confirmed ARI was statistically signifi-
cant. Secondary endpoint analysis also revealed a statistically 
significant increase in laboratory-confirmed influenza illness 
and laboratory-confirmed ARI due to influenza and respiratory 
syncytial virus, amounting to an 89% lower relative risk for ARI 
in the CVT-E002 group as compared to the placebo group. 
A later study using an extract standardized to contain 90% 
poly-furanosyl-pyranosyl-saccharides, commercially termed 
COLD-fX®, was conducted with institutionalized adults aged 
65 years or older.59 The frequency and duration of ARI during 
the first 2 months of the study was similar in the 2 groups, but 
during the following 2 months significantly fewer subjects in the 
COLD-fX group (32%) reported ARI compared to the placebo 
group (62%). The duration of symptoms during these latter 2 
months was significantly shorter in the COLD-fX group than 
the placebo group (5.6 days in the COLD-fX group vs. 12.6 days 
in the placebo group). The authors of these studies concluded 
that COLD-fX supplementation to immunocompetent seniors 
during an early “cold and flu” season could help to reduce the 
frequency and duration of respiratory symptoms related to ARI: 
“a safe natural therapeutic means for the prevention of ARI in 
healthy seniors.” 
In the year intervening between the two above publications, an 
RCT was conducted at the onset of the influenza season with 323 
healthy adults aged 18-65 years who had a history of at least two 
colds in the previous year.47 Results from the RCT showed a 13% 
reduction in the absolute risk of getting recurrent colds that meet 
the Jackson criteria. The mean number of Jackson-verified colds 
per person was significantly less in the ginseng-derived saccharide-
treated group than in the placebo group.60 Fewer subjects in the 
saccharide group than in the placebo group reported contracting 
at least 1 cold during the study, but the difference was not statis-
tically significant. However, there was a significant difference in 
the recurrence of colds, with 10% in the saccharide group having 
more than one cold compared with 23% in the placebo group. 
Ginseng-treated subjects had less severe symptoms and were sick 
for fewer days. However, while this study was of excellent meth-
odological quality and reported a 13% reduction in the risk of 
contracting a cold, it does not seem particularly clinically valu-
able. More promising perhaps is that “the total symptom score 
was 31% lower and the total number of days on which symptoms 
were reported was 34% less in the COLD-fX group than in the 
placebo group over the 4-month intervention period.” 
Presumably, based on the evaluation of clinical data (i.e., 10 
years of research, including 7 clinical trials submitted by CV 
Technologies), Health Canada ruled that the company can 
continue to market the COLD-fX product as “helping to reduce 
the frequency, severity and duration of cold and flu symptoms by 
boosting the immune system.”61 
Conclusion
While there is ample clinical evidence in support of the benefi-
cial influence of American ginseng in treating Type 2 diabetes 
and preventing cold and flu attacks, comparable data on behalf 
of Asian ginseng are wanting. In vitro and animal studies also 
support an anti-cancer potential for steam-processed (red) P. 
ginseng root and an extract of P. quinquefolius root has been 
shown synergistically to inhibit the growth of MCF-7 human 
breast cancer cells. Overall, much more effort needs to be 
expended toward standardization of ginseng preparations so as to 
ensure reliable repeatable therapeutic effect. 
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